Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.53 -0.05 (-0.38%)
Streaming Delayed Price Updated: 12:31 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
European Cannabis Q1 2022 Quarterly Update
Just like the United States’ state-by-state movement, Europe is moving country-by-country toward providing access to cannabis. 
Via Talk Markets
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories & MediCane Health To Launch Medical Cannabis Products In Germany
Dr. Reddy's Laboratories Ltd.  (NYSE: RDY)  and MediCane Health Inc. announced the launch of its medical cannabis product in Germany. 
Via Benzinga
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
From MediCane Health Inc.
Via Business Wire
Flood Helping Ukraine
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
Up On Bad News
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
The Ruble Is Rubble
MSCI says Russian companies are 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the... 
Via Benzinga
Putin on the brink
For the first time in history, Swiss banks have penalized account owners for political actions and joined a SWIFT boycott. 
Via Talk Markets
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
Give peace a chance
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today. 
Via Talk Markets
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH
Pharmaceutical company Dr. Reddy's Laboratories Ltd. (NYSE:RDY) has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from... 
Via Benzinga
Weakened Tech Stocks
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks. 
Via Talk Markets
Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Included in S&P Global’s Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for the 5th Year in a Row
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
The Last Day In January
The market is suspicious of the moves up to right matters. 
Via Talk Markets
Earnings Scheduled For January 28, 2022
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its third quarter. • LyondellBasell Industries (NYSE:... 
Via Benzinga
Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters
India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, ... 
Via Benzinga
Happy New Year - Sunday Edition
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
Market Trend: Erratic And Unreliable
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
A Bit Of Good News
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%. 
Via Talk Markets
Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
From Prestige BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.